Canadian researchers at the University of Alberta are trying to understand why the weight-loss drugs Ozempic and Wegovy, whose active ingredient is semaglutide, produce striking results in some patients while barely helping others. The team is testing the hypothesis that metabolic adaptation — the body shifting into energy-saving mode as it sheds weight — plays a key role in how well the therapy works, infohub.kz reports.
According to ScienceDaily, the issue is a hidden energy-saving mode that slows metabolism during weight loss and blunts the effect of semaglutide-based medicines.
Clinical observations show that weekly doses of glucagon-like peptide-1 (GLP-1) receptor agonists over 68 weeks, combined with lifestyle changes, cut body weight by an average of 15 percent by suppressing appetite and boosting feelings of fullness. But as patients lose weight, both fat and lean tissue shrink, so the body burns fewer calories at rest. In some cases the process is amplified by adaptive thermogenesis, leading to a plateau effect.
To measure calorie expenditure precisely — at rest, after meals and during exercise — the scientists are using a rare piece of equipment: a whole-room indirect calorimeter. The team is now recruiting volunteers with insulin resistance and type 2 diabetes who are starting semaglutide, in order to track changes in their metabolism and body composition over six months. The findings could help identify non-responders in advance and tailor treatment to them.
This material is for informational purposes only and is not a guide to action. Drugs based on semaglutide and other glucagon-like peptide-1 (GLP-1) receptor agonists are serious prescription medicines with a wide range of contraindications and side effects. Using them without a specialist's prescription can cause serious harm to health. Always consult a qualified physician before starting any treatment or taking any medication.


